Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Greene

Showing results (741-750 of 1,076) with videos related to

Pageof 108
Sort By:
Biochemical Pharmacology|August 9, 2002
Structural and functional characterization of an acidic platelet aggregation inhibitor and hypotensive phospholipase A(2) from Bothrops jararacussu snake venomSílvia H Andrião-Escarso, Andreimar M Soares, Marcos R M Fontes, et al.
Clinical Cardiology|May 29, 2025
Real-World Health Care Resource Utilization and Costs Associated With First-Line Dronedarone Versus First-Line Ablation in Adults With Atrial FibrillationStephen J Greene, Samantha Schilsky, Andrew W Roberts, et al.
European Journal of Heart Failure|July 13, 2013
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialStephen J Greene, Mihai Gheorghiade, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|May 11, 2024
Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trialStephen J Greene, RaKavius Chambers, Joseph B Lerman, et al.
ESC Heart Failure|January 14, 2022
Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failureMuhammad Shariq Usman, Muhammad Shahzeb Khan, Gregg C Fonarow, et al.
American Heart Journal|September 28, 2021
Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018Husam M Salah, Abdul Mannan Khan Minhas, Muhammad Shahzeb Khan, et al.
Immunogenetics|January 1, 1997
Genomic organization, chromosomal mapping, and analysis of the 5' promoter region of the human MAdCAM-1 geneE Leung, R W Berg, R Langley, et al.
Journal of Cardiac Failure|February 24, 2025
Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-AnalysisSaad Ahmed Waqas, Muhammad Umer Sohail, Muhammad Saad, et al.
Comprehensive Psychiatry|June 28, 2024
We've all been wrong about provisional tic disorderSarah C Grossen, Amanda L Arbuckle, Emily C Bihun, et al.
European Journal of Heart Failure|December 12, 2018
Medication dosing for heart failure with reduced ejection fraction - opportunities and challengesCatherine N Marti, Gregg C Fonarow, Stefan D Anker, et al.
Pageof 108

Showing results (741-750 of 1,076) with videos related to

Sort By:
Pageof 108
Biochemical Pharmacology|August 9, 2002
Structural and functional characterization of an acidic platelet aggregation inhibitor and hypotensive phospholipase A(2) from Bothrops jararacussu snake venomSílvia H Andrião-Escarso, Andreimar M Soares, Marcos R M Fontes, et al.
Clinical Cardiology|May 29, 2025
Real-World Health Care Resource Utilization and Costs Associated With First-Line Dronedarone Versus First-Line Ablation in Adults With Atrial FibrillationStephen J Greene, Samantha Schilsky, Andrew W Roberts, et al.
European Journal of Heart Failure|July 13, 2013
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialStephen J Greene, Mihai Gheorghiade, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|May 11, 2024
Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trialStephen J Greene, RaKavius Chambers, Joseph B Lerman, et al.
ESC Heart Failure|January 14, 2022
Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failureMuhammad Shariq Usman, Muhammad Shahzeb Khan, Gregg C Fonarow, et al.
American Heart Journal|September 28, 2021
Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018Husam M Salah, Abdul Mannan Khan Minhas, Muhammad Shahzeb Khan, et al.
Immunogenetics|January 1, 1997
Genomic organization, chromosomal mapping, and analysis of the 5' promoter region of the human MAdCAM-1 geneE Leung, R W Berg, R Langley, et al.
Journal of Cardiac Failure|February 24, 2025
Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-AnalysisSaad Ahmed Waqas, Muhammad Umer Sohail, Muhammad Saad, et al.
Comprehensive Psychiatry|June 28, 2024
We've all been wrong about provisional tic disorderSarah C Grossen, Amanda L Arbuckle, Emily C Bihun, et al.
European Journal of Heart Failure|December 12, 2018
Medication dosing for heart failure with reduced ejection fraction - opportunities and challengesCatherine N Marti, Gregg C Fonarow, Stefan D Anker, et al.
Pageof 108